| EME |
Report |
Q2 2026 diluted EPS |
BEAT |
pred ~$7.55 vs. cons $7.23 |
MEDIUM |
| EME |
Report |
Q2 2026 revenue |
BEAT |
pred ~$4.84B vs. cons $4.71B |
MEDIUM |
| EME |
Report |
Q2 2026 remaining performance obligations |
BEAT |
pred ~$16.10B vs. cons $15.90B |
LOW |
| EME |
Guide |
FY2026 revenue guidance midpoint |
BETTER |
guide ~$19.15B vs. cons $19.00B (FY2026) |
MEDIUM |
| EME |
Guide |
FY2026 diluted EPS guidance midpoint |
BETTER |
guide ~$29.90 vs. cons $29.37 (FY2026) |
MEDIUM |
| EME |
Return |
Day-1 residual (stock − beta × S&P 500) |
+6.0% |
— |
MEDIUM |
| EME |
Return |
5-day cumulative residual |
+8.5% (FOLLOW-THROUGH) |
A broad beat, near-record RPOs and higher FY2026 guidance should lift FY2026/FY2027 estimates; the sharp pre-report selloff creates room for continued recovery rather than a rapid fade. |
MEDIUM |